The company’s clinical stage product, LTX-315, reshapes tumor microenvironment through an effective release of potent immune stimulants and tumor antigens. Through the ‘release and reshape’ effect of LTX-315, the tumors are sensitized to other types of therapies opening up for a variety of combination treatments.